Literature DB >> 2424284

Azapyrimidine nucleosides: metabolism and inhibitory mechanisms.

A Cihák, J Vesely, J Skoda.   

Abstract

Triazine nucleosides represent highly active compounds affecting different cellular processes. While 6-azauridine displays a rather selective inhibitory effect, biological action of 5-azacytidine reflects the polyvalent inhibitory mechanism of the drug (interaction with pyrimidine synthesis de novo, incorporation into RNA and DNA, depressed maturation of ribosomal RNA, inhibition of RNA and DNA methylation, etc.) and the analog displays pronounced cytostatic and immunosuppressive activity. 5-Aza-2'-deoxycytidine action is directed against DNA synthesis similar to that of 5-azacytosine arabinoside. N4-Substituted derivatives of 5-azacytidine affect gastric secretion and together with 5-azacytosine and 5-azacytidine represent a new type of drugs with antiulcer activity. 6-Amino-5-azacytosine nucleosides interfere with the metabolism of purines rather than pyrimidines as evidenced by the character of their inhibitory mechanism and measurement of conformation. 6-Azauridine (as 2',3',5'-triacetate) and 5-azacytidine were used with certain success in human chemotherapy, the first one as a drug affecting recalcitrant psoriasis, the second one for the treatment of different forms of leukemia. The inhibitory mechanisms of individual azapyrimidine nucleosides are discussed in relation to their known biological effects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2424284     DOI: 10.1016/0065-2571(85)90085-8

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN: 0065-2571


  7 in total

1.  Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity.

Authors:  S Sierra; M Dávila; P R Lowenstein; E Domingo
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Chemical interference with DSIF complex formation lowers synthesis of mutant huntingtin gene products and curtails mutant phenotypes.

Authors:  Ning Deng; Yun-Yun Wu; Yanan Feng; Wen-Chieh Hsieh; Jen-Shin Song; Yu-Shiuan Lin; Ya-Hsien Tseng; Wan-Jhu Liao; Yi-Fan Chu; Yu-Cheng Liu; En-Cheng Chang; Chia-Rung Liu; Sheh-Yi Sheu; Ming-Tsan Su; Hung-Chih Kuo; Stanley N Cohen; Tzu-Hao Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-01       Impact factor: 12.779

3.  Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.

Authors:  Gautam Borthakur; Xuelin Huang; Hagop Kantarjian; Stefan Faderl; Farhad Ravandi; Alessandra Ferrajoli; Ritva Torma; Gail Morris; Donald Berry; Jean-Pierre Issa
Journal:  Leuk Lymphoma       Date:  2010-01

4.  Targeting histone demethylases in cancer therapy.

Authors:  Steven Grant
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

Review 5.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.

Authors:  William B Parker
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

Review 6.  Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy.

Authors:  Yasuhiro Oki; Jean-Pierre J Issa
Journal:  Int J Hematol       Date:  2007-11       Impact factor: 2.490

7.  Identification of hypermethylation in hepatocyte cell adhesion molecule gene promoter region in bladder carcinoma.

Authors:  Jia Tao; Qi Liu; Xiaohou Wu; Xin Xu; Yanyi Zhang; Qiuju Wang; Chunli Luo
Journal:  Int J Med Sci       Date:  2013-11-11       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.